Cipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA approval. The company is resolving regulatory issues with its domestic plants and focusing on new therapeutic areas and tech-based solutions. Cipla is also addressing antimicrobial resistance and expanding its digital health initiatives. nnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-expects-to-commence-supplies-to-us-from-china-plant-later-this-year/articleshow/112078176.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth was offset by trade generics softness. Cipla's South Africa revenue grew 19% YoY in local currency terms. Net profit rose 17.4% to Rs 1,178 crore. nnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ciplas-north-america-business-revenue-hits-record-high-in-q1-at-250-million/articleshow/112040601.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Mumbai: Drug maker Cipla has received an additional tax demand of Rs 773.44 crore from the income tax department for assessment years 2015-16 to 2022-23, the drug maker said in a stock exchange statement on Tuesday.
The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastrointestinal therapies. According to market researcher Pharmarack, these therapies saw double-digit growth compared to June 2023.
FDA Issues form 483 to Cipla Goa
Cipla Limited announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) Limited will invest an additional € 3 million in Ethris, a global leader in delivering mRNAs directly to the respiratory system. This additional investment through a convertible loan will accelerate Cipla's participation in the mRNA space.
The Department of Pharmaceuticals (DoP) has asked the National Pharmaceutical Pricing Authority (NPPA) to recalculate the ceiling prices of antiretroviral medicine lamivudine 100 mg tablets, anti-asthma drug montelukast 4 mg tablets and cholesterol lowering drug atorvastatin 10 mg tablets, following review petitions filed by Cipla Ltd against the previous price fixation.
Indian drugmakers to see FY25 revenue boost in key US market
Cipla Limited and its wholly owned subsidiary Cipla USA, announced that it has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States Food and Drug Administration (USFDA).